Consumption trends of alpha-lipoic acid: drugs vs. dietary supplements in the Republic of Serbia

Milana Vuković; Jelena Jovičić Bata; Nemanja Todorović; Jelena Čanji Panić; Dunja Vesković; Mladena Lalić-Popović

doi:10.5937/arhfarm74-49835

Milana Vuković University of Novi Sad – Faculty of Medicine, Department of Pharmacy
Jelena Jovičić Bata University of Novi Sad – Faculty of Medicine, Department of Pharmacy
Nemanja Todorović University of Novi Sad – Faculty of Medicine, Department of Pharmacy
Jelena Čanji Panić University of Novi Sad – Faculty of Medicine, Department of Pharmacy
Dunja Vesković , Clinical Center of Vojvodina, Clinic for Dermatology; University of Novi Sad – Faculty of Medicine, Department of Dermatovenereology
Mladena Lalić-Popović University of Novi Sad – Faculty of Medicine, Department of Pharmacy; Centre for Medical and Pharmaceutical Investigations and Quality Control (CEMPhIC)

DOI: https://doi.org/10.5937/arhfarm74-49835

Keywords: alpha-lipoic acid, dietary supplements, consumption trends, regulation, antioxidants

Abstract

On the Serbian market, alpha-lipoic acid (ALA) is available in 7 drug formulations and over 50 dietary supplements (DS). This study aimed to analyze and compare the consumption of ALA drugs and DS. The data on drug consumption were obtained from the annual reports of the Medicines and Medical Devices Agency of Serbia, while the data for DS were sourced from IMS Health's monthly audit reports. The consumption of ALA drugs significantly increased during 2010-2016 (R² = 0.753, F(1, 5) = 15.219, p = 0.011), with a notable drop observed in 2017. The consumption of ALA DS surged by 156.67% from 2018 to 2020, reaching 0.77 DDD/1000 inhabitants/day, with a notable increase observed at the end of 2020. From January to October 2021, the consumption doubled compared to the same period in 2020, reaching 1 DDD/1000 inhabitants/day. The increase in ALA drug consumption during 2010-2016 paralleled the registration and clinical adoption of ALA drugs. A significant drop in 2017 might have resulted from registering new ALA DS. However, during 2018-2020, ALA drugs were more commonly consumed compared to ALA DS. The increased consumption of ALA DS at the end of 2020 was associated with the COVID-19 epidemic. While both drugs and DS offer 600 mg ALA doses, only drug regulations ensure quality and efficacy, highlighting the need for stricter regulations on DS to enhance consumer safety and information.

References

Republički fond za zdravstveno osiguranje [Internet]. [cited 2023 Jun 5]. Pretraga liste lekova. Available from: https://www.rfzo.rs/index.php/osiguranalica/lekovi-info/pretraga-liste-lekova.

EU Register on nutrition and health claims [Internet]. [cited 2023 Jun 6]. Available from: https://ec.europa.eu/food/food-feed-portal/backend/claims/files/euregister.pdf.

The Rulebook on Nutrition and Health Claims Listed on Food Labels. Official Gazette of RS, 51/18, 103/18, 110/23 2023.

The Rulebook on Nutrition and Health Claims Listed on Food Labels [Internet]. Official Gazette of RS, 51/18, 103/18, 110/23. Appendix 2 [cited 2024 Jun 4]. Available from: https://reg.pravno-informacioni-sistem.rs/api/Attachment/prilozi/436571/p2.html.

The Rulebook on Nutrition and Health Claims Listed on Food Labels [Internet]. Official Gazette of RS, 51/18, 103/18, 110/23. Appendix 2a [cited 2024 Jun 4]. Available from: https://reg.pravno-informacioni-sistem.rs/api/Attachment/prilozi/436571/p2a.html.

Sayıner S, Şehirli AÖ, Serakıncı N. Alpha Lipoic Acid as a Potential Treatment for COVID-19 – A Hypothesis. Curr Top Nutraceutical Res. 2021;19(2):172–5.

Dragomanova S, Miteva S, Nicoletti F, Mangano K, Fagone P, Pricoco S, et al. Therapeutic Potential of Alpha-Lipoic Acid in Viral Infections, including COVID-19. Antioxidants (Basel). 2021 Aug 16;10(8):1294.

Bradbury J, Wilkinson S, Schloss J. Nutritional Support During Long COVID: A Systematic Scoping Review. J Integr Complement Med. 2023 Nov;29(11):695-704.

Supply and Consumption of Medicines for Human Use in the Republic of Serbia in 2010. Belgrade; 2011.

Supply and Consumption of Medicines for Human Use in the Republic of Serbia in 2011. Belgrade; 2012.

Supply and Consumption of Medicines for Human Use in the Republic of Serbia in 2012. Belgrade; 2013.

Supply and Consumption of Medicines for Human Use in the Republic of Serbia in 2013. Belgrade; 2014.

Supply and Consumption of Medicines for Human Use in the Republic of Serbia in 2014. Belgrade; 2015.

Supply and Consumption of Medicines for Human Use in the Republic of Serbia in 2015. Belgrade; 2016.

Supply and Consumption of Medicines for Human Use in the Republic of Serbia in 2016. Belgrade; 2017.

Supply and Consumption of Medicines for Human Use in the Republic of Serbia in 2017. Belgrade; 2018.

Supply and Consumption of Medicines for Human Use in the Republic of Serbia in 2018. Belgrade; 2019.

18. Supply and Consumption of Medicines for Human Use in the Republic of Serbia in 2019. Belgrade; 2020.

Supply and Consumption of Medicines for Human Use in the Republic of Serbia in 2020. Belgrade; 2021.

Introduction to Drug Utilization Research [Internet]. Oslo; 2003 [cited 2021 Nov 11]. Available from: https://www.whocc.no/filearchive/publications/drug_utilization_research.pdf.

Available IQVIA Data [Internet]. [cited 2021 Nov 11]. Available from: https://www.iqvia.com/

insights/the-iqvia-institute/available-iqvia-data.

Estimates of population [Internet]. [cited 2021 Nov 15]. Available from: https://www.stat.gov.rs/en-US/oblasti/stanovnistvo/procene-stanovnistva.

Incidence and mortality of diabetes in Serbia 2021 [Internet]. [cited 2021 Nov 15]. Available from: https://www.batut.org.rs/download/publikacije/Incidencija%20i%20mortalitet%20od%20dijabetesa%20u%20Srbiji%202021.pdf.

Karuranga S, Malanda B, Saeedi P, Salpea P, editors. IDF Diabetes Atlas [Internet]. Ninth edition. Brussels: International Diabetes Federation; 2019 [cited 2023 Jun 5]. Available from: https://diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf.

Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004 Feb;21(2):114–21.

Salehi B, Berkay Yılmaz Y, Antika G, Boyunegmez Tumer T, Fawzi Mahomoodally M, Lobine D, et al. Insights on the Use of α-Lipoic Acid for Therapeutic Purposes. Biomolecules. 2019 Aug 9;9(8):356.

List of Dietary Supplements Updated as of June 2018. Belgrade; 2018.

The Rulebook on the Health Safety of Dietary Products. Official Gazette of RS, 45/10, 27/11, 50/12, 21/15,75/15, 7/17,103/2018 2018.

Breithaupt-Grögler K, Niebch G, Schneider E, Erb K, Hermann R, Blume HH, et al. Dose-proportionality of oral thioctic acid — coincidence of assessments via pooled plasma and individual data. Eur J Pharm Sci. 1999 Apr;8(1):57–65.

Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009 Oct;1790(10):1149–60.

The Rulebook on the Method of Advertising Medicines or Medical Devices. Official Gazette of RS, 102/2018 2018.

Rochette L, Ghibu S. Mechanics Insights of Alpha-Lipoic Acid against Cardiovascular Diseases during COVID-19 Infection. Int J Mol Sci. 2021 Jul 26;22(15):7979.

Hummel T, Heilmann S, Hüttenbriuk KB. Lipoic acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract. Laryngoscope. 2002 Nov;112(11):2076–80.

Pelemiš M, Stevanović G, Turkulov V, Matijašević J, Milošević B, Milošević I. PROTOKOL ZA LEČENJE PACIJENATA SA COVID-19 VERZIJA 8 [Internet]. [cited 2021 Nov 30]. Available from: https://dzgm.rs/covid19.php.

Pelemiš M, Stevanović G, Turkulov V, Matijašević J, Milošević B, Milošević I. PROTOKOL ZA LEČENJE PACIJENATA SA COVID-19 VERZIJA 9 [Internet]. [cited 2021 Nov 30]. Available from: https://www.dzsvenac.rs/sluzbeno/images/dokumenta/covid/Terapijski-protokol-COVID-19-18082020-verzija9.pdf.

Stevanović G, Turkulov V, Matijašević J, Milošević B, Milošević I, Gajović O, et al. PROTOKOL ZA LEČENJE PACIJENATA SA COVID-19 [Internet]. [cited 2023 Jun 5]. Available from: https://zzzzsbg.rs/wp-content/uploads/2020/04/Terapijski-protokol-COVID-19-konacna-verzija.pdf.

Hopkins C, Alanin M, Philpott C, Harries P, Whitcroft K, Qureishi A, et al. Management of new onset loss of sense of smell during the COVID-19 pandemic - BRS Consensus Guidelines. Clin Otolaryngol. 2021 Jan;46(1):16–22.

Daily New Cases in Serbia. Worldometer. [Internet]. [cited 2021 Nov 28]. Available from: https://www.worldometers.info/coronavirus/country/serbia/.

Understanding the infodemic and misinformation in the fight against COVID-19 . 2020. [Internet]. [cited 2023 Nov 15]. Available from: https://chrome-extension://efaidnbmnnnibpcajpcglcle

findmkaj/https://iris.paho.org/bitstream/handle/10665.2/52052/Factsheet-infodemic_eng.pdf.

Cure E, Cumhur Cure M. Alpha-lipoic acid may protect patients with diabetes against COVID-19 infection. Med Hypotheses. 2020 Oct;143:110185.

Bahrami Moghadam H, Maniati M. Alpha lipoic acid: A treatment option for diabetic patients with Covid 19. Health Tech Assess Act. 2021 Jun 9;4(3):e.6352.